Bone erosion, a common side-effect of rheumatoid arthritis, can be prevented by using a combination of close patient monitoring and individualized therapeutic regimens that include agents to block cytokines, block osteoclasts, or target abnormal cellular reactions.
Bone erosion, a common side-effect of rheumatoid arthritis, can be prevented by using a combination of close patient monitoring and individualized therapeutic regimens that include agents to block cytokines, block osteoclasts, or target abnormal cellular reactions.
Ellen Gravallese, MD, from the University of Massachusetts Medical School, discussed ways to treat rheumatoid arthritis and prevent bone erosion at the 2014 American Society of Bone and Mineral Research Conference in Houston, Texas.
In rheumatoid arthritis with hand involvement, articular erosions predict disability. These abnormalities can ultimately be seen as anatomic deformities, but they can also be identified on radiography when progression is subclinical. Parameters associated with increased risk of radiographic progression, include elevated inflammatory markers, bone erosion at presentation, genetic risk, the presence or absence of autoantibodies, and smoking.
Bone edema represents inflammation into the marrow space and the degree of edema correlates with inflammation and erosion. So, as inflammation improves with treatment, so does edema. Conversely, when inflammation worsens in the marrow space, it leads to erosion.
Dr Gravallese described how effective monitoring of patients using biochemical, radiologic, and clinical markers allows for individualized treatment. In the TICORA trial, rheumatoid arthritis patients were randomized to intensive management versus routine care. The study found that patients who were evaluated using objective instruments (such as clinical and radiographic findings) to assess joint inflammation, had improved outcomes.
Dr Gravalle also discussed the use of biomarkers in managing rheumatoid arthritis. For one study that showed dissociation between clinical remission and imaging, she said, “I would argue that it is not so important that osteoblasts go in and heal erosion sites, but healing erosions could be an important biomarker”.
There are currently three broad therapeutic classes that are being used to treat rheumatoid arthritis: agents can block cytokines, osteoclasts, or cells. Therapeutics that block cytokines include those that target IL-1, Tumor Necrosis Factor (TNF), and IL-6 (for example, tocilizumab). Therapeutic agents that have cellular targets include rituximab (B cells), abatacept (T cell co-stimulation) and tofacitinib.
Although these medications have complications, including infections and hyperlipidemia, targeted therapy against specific cytokines is a novel way of treating patients with rheumatoid arthritis. Clinical trials are currently enrolling patients who have previously been refractory to conventional treatment.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More